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Introduction {#sec1}
============

Thyroid hormones (TH, including thyroxine, or T4, and 3,3′,5-triiodo-L-thyronine, or T3, its active metabolite) exert a broad influence on neurodevelopment. If untreated soon after birth, congenital hypothyroidism, i.e. early TH deficiency, affects brain development and a number of cognitive functions ([@bib48]). Severe cases display mental retardation, autism spectrum disorders (ASD), and epilepsy ([@bib18]). TH mainly acts by binding to nuclear receptors called TRα1, TRβ1, and TRβ2, which are encoded by the *THRA* and *THRB* genes (*Thra* and *Thrb* in mice, formerly *TRα* and *TRβ*). These receptors form heterodimers with other nuclear receptors, the retinoid X receptors (RXRs), and bind chromatin at specific locations (thyroid hormone response elements), acting as TH-dependent transcription activators of neighboring genes. In the developing brain, the predominant type of receptor is TRα1 ([@bib7]). Accordingly, *THRA* germline mutations, which have currently been reported in only 45 patients, cause a syndrome named RTHα (resistance to thyroid hormone due to *THRA* mutations), resembling congenital hypothyroidism, with mental retardation and a high occurrence of ASD and epilepsy ([@bib52]).

Cellular alterations caused by early TH deficiency or germline mutations have been extensively studied in rodents. Many neurodevelopmental processes depend on proper TH signaling, and virtually all glial and neuronal cell populations are affected by TH deficiency ([@bib4], [@bib6]). However, in the mouse cerebellum, we have previously found that, although *Thra* expression is ubiquitous in this brain region, only a subset of cell types displayed a direct, cell-autonomous, response to TH ([@bib16]). More specifically, Cre/*loxP* technology, used to express a dominant-negative variant of TRα1 (TRα1^L400R^), has provided genetic evidence that the cell-autonomous influence of TRα1 is limited to astrocytes and GABAergic neurons ([@bib16]). By altering the differentiation of GABAergic neurons, TRα1^L400R^ prevented the secretion of several growth factors and neurotrophins. This indirectly altered the proliferation and differentiation of granule cells and oligodendrocytes ([@bib44], [@bib45]). Therefore, GABAergic neurons occupy a pivotal position during cerebellum development, amplifying the initial TH signal. This allows TH to synchronize cellular interactions and the maturation of neuronal networks during the first post-natal weeks ([@bib20]). As defects in TH signaling are known to alter GABAergic neurons outside the cerebellum ([@bib3], [@bib28], [@bib56]), we asked whether the direct role of TH in GABAergic neurons, initially observed in the cerebellum, could be generalized to other brain regions.

In the present study, we used the same genetic strategy to block TH response in the entire GABAergic lineage by expressing TRα1^L400R^ from early developmental stages specifically in GABAergic neurons in all brain areas. This had dramatic neurodevelopmental consequences on the development of the GABAergic system and caused lethal epileptic seizures. Genome-wide analyses allowed us to pinpoint the genetic defects induced by the mutation and to identify a small set of genes activated by TH in GABAergic neurons. These genes are likely to play a key role in the neurodevelopmental function of TH.

Results {#sec2}
=======

Mouse Models Designed to Target TRα1 in GABAergic Neurons {#sec2.1}
---------------------------------------------------------

We generated new mouse models by combining existing and novel "floxed" *Thra* alleles with the *Gad2Cre* transgene ([Figure 1](#fig1){ref-type="fig"}A). This transgene drives the expression of Cre recombinase in all GABAergic neurons and their progenitors from an early prenatal stage (around E12.5) ([@bib49]). In the context of the modified *Thra* alleles used in the present study, Cre recombinase eliminates a transcriptional stop cassette and triggers the expression of TRα1 variants. The *Thra*^*AMI*^ allele (formerly *TRα*^*AMI*^) ([@bib46]) encodes TRα1^L400R^ ([Figure 1](#fig1){ref-type="fig"}B), which exerts a permanent transcriptional repression on target genes, even in the presence of TH. This is due to its inability to recruit transcription coactivators, which normally interact with the C-terminal helix (AA 398-407) of TRα1, and permanent interaction with transcription corepressors ([Figure S1](#mmc1){ref-type="supplementary-material"}). This allelic design, which eliminates alternate splicing, increases the expression of the mutant receptor over that of the wild-type receptor, as shown by comparing peak surfaces after Sanger sequencing: in the striatum of *Thra*^*AMI/gn*^ mice, the *Thra*^*AMI*^ allele represents 65 ± 4% of all *Thra* transcripts (mean ± standard deviation, *n* = 4; see also ([@bib38])). This ensures a complete inhibition of TH response in heterozygous cells ([@bib38]). As complete deprivation of TH ([@bib35]), ubiquitous expression of TRα1^L400R^ results in the death of heterozygous mice 2--3 weeks after birth ([@bib46]). The second modified *Thra* allele, named *Thra*^*Slox*^, differs from *Thra*^*AMI*^ only by an additional frameshift mutation, which eliminates the C-terminal helix of TRα1 ([@bib38]). As for *Thra*^*AMI*^, expression of the *Thra*^*Slox*^ allele exceeds that of the wild-type *Thra* allele: in the striatum of *Thra*^*Slox/gn*^ mice, the *Thra*^*Slox*^ allele represents 59 ± 1% of all *Thra* transcripts (mean ± standard deviation, *n* = 6). The *Thra*^*Slox*^ allele encodes TRα1^E395fs401X^ ([Figure 1](#fig1){ref-type="fig"}B), which is nearly identical to a pathological variant found in a patient ([@bib53], [@bib54]). TRα1^E395fs401X^ is expected to be functionally equivalent to TRα1^L400R^ and behaves similarly in *in vitro* assays ([@bib38]). The third modified *Thra* allele used in the present study is *Thra*^*TAG*^*,* a novel construct that encodes a functional receptor, TRα1^TAG^, with a fragment of protein G at its N-terminus ([@bib10]). This tag has a high affinity for IgGs, which makes it suitable to address chromatin occupancy ([@bib13]). Transient expression assays show that the N-terminal GS tag does not impair the transactivation capacity of TRα1 ([Figure S2](#mmc1){ref-type="supplementary-material"}). Double heterozygous mice, combining the presence of *GADad2Cre* and of a modified *Thra* allele, express TRα1^L400R^, TRα1^E395fs401X^, or TRα1^TAG^ in the GABAergic cell lineage only. They will be respectively designated as *Thra*^*AMI/gn*^, *Thra*^*Slox/gn*^, and *Thra*^*TAG/gn*^ in the following,*/gn* being used to indicate that the modified *Thra* alleles were expressed specifically in GABAergic neurons. In all phenotyping experiments, littermates carrying only *Thra*^*AMI*^*, Thra*^*Slox*^, or *GAD2Cre* were used as controls.Figure 1*Thra* Alleles and Survival Curves(A) Schematic representation of *Thra* alleles in *Thra*^*AMI*^, *Thra*^*Slox*^ and *Thra*^*TAG*^ mice. In all 3 alleles, the coding sequence is preceded with a floxed stop cassette (PGKNeo Poly(A). The intronless structure eliminates alternate splicing and internal promoter and thus prevents the production of TRα2, TRΔα1, and TRΔα2 non-receptor protein. The dispensable IRES Tau-lacZ reporter part was not included in the *Thra*^*TAG*^ construct.(B) C-terminal amino acid sequence of *Thra* gene products used in the present study, starting from AA393. Shaded amino acids differ from wild-type TRα1. *Thra*^*AMI*^ mutation results in a single amino acid substitution within TRα1 helix 12. *Thra*^*Slox*^ mutation is a deletion resulting in a +1 frameshift, leading to elimination of helix 12, as in several RTHα patients.(C) Survival curves of mice expressing a mutated TRα1 in GABAergic neurons (green and red lines) and of control littermates (black line).See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"} and [Videos S1](#mmc3){ref-type="supplementary-material"} and [S2](#mmc4){ref-type="supplementary-material"}.

Post-natal Lethality Caused by Thra Mutations in GABAergic Neurons {#sec2.2}
------------------------------------------------------------------

Born at the expected frequency, *Thra*^*AMI/gn*^ mice did not usually survive beyond the third post-natal week ([Figure 1](#fig1){ref-type="fig"}C). Video recording of litters in their home cage indicated that most mice started to display epileptic seizures a few days before death. Occasionally, sudden death was observed at the end of a seizure. In most cases, seizures impeded maternal care and this likely precipitated the death of the pups ([Videos S1](#mmc3){ref-type="supplementary-material"} and [S2](#mmc4){ref-type="supplementary-material"}). Although lethality was also observed in *Thra*^*Slox/gn*^ mice ([Figure 1](#fig1){ref-type="fig"}C), about one-third of these mice survived into adulthood. Adult *Thra*^*Slox/gn*^ mice did not display any obvious epileptic seizure anymore. However, their locomotor behavior was significantly altered, as evidenced in an open-field test ([Figure S3](#mmc1){ref-type="supplementary-material"}). These observations show that, although the two mutations are expected to be equivalent, TRα1^E395fs401X^ is less detrimental than TRα1^L400R^.

Video S1. Representative Video Illustrating the Occurrence of an Epileptic Seizure in a *Thra*^AMI/gn^ Mouse Pup at Postnatal Day 17, Related to Figure 1The seizure occurred during the dark phase of the photoperiod and was video recorded using infrared lighting.

Video S2. Representative Video Illustrating the Occurrence of an Epileptic Seizure in a *Thra*^AMI/gn^ Mouse Pup at Postnatal Day 13, Related to Figure 1Note the unsuccessful attempts of the mother to drag the pup back to the nest.

A Global Impairment in the Differentiation of GABAergic Neurons {#sec2.3}
---------------------------------------------------------------

In order to label neurons of the GABAergic lineage in a generic way, we combined the *Thra*^*AMI*^ and *Gad2Cre* alleles with the *Rosa-tdTomato* transgene, which enabled to trace the cells in which *Cre/loxP* recombination had taken place. The density of tdTomato + cells was not reduced in *Thra*^*AMI/gn*^ *Rosa-tdTomato* mice, arguing against a possible alteration in the proliferation, migration, or survival of GABAergic neuron progenitors. In the hippocampus, notably in the dentate gyrus, the number of tdTomato + cells was even increased ([Figure 2](#fig2){ref-type="fig"}).Figure 2Expression of the tdTomato Fluorescent Protein in *TRα*^*AMI/gn*^*Rosa-tdTomato* and Control Littermates at PND14(A) Low-magnification images illustrating the relative fluorescence intensity in the cortex (Cx), striatum (Str), and hippocampus (Hp) in *GAD2Cre Rosa-tdTomato* mice.(B) Representative images allowing to compare the density of tdTomato positive cells in selected brain regions in *Thra*^*AMI/gn*^*Rosa-tdTomato* and control littermates (*GAD2Cre Rosa-tdTomato)*.(C) Relative density of tdTomato + cells in *Thra*^*AMI/gn*^*Rosa-tdTomato* ("M" in the graph stands for mutants, filled triangles; red lines for the mean and standard deviation) and control littermates ("C", empty circles; blue lines for the mean and standard deviation) at PND14. \*p \< 0.05.

We used immunohistochemistry to detect alterations of GABAergic neuron differentiation at postnatal day 14 (PND14) in various brain areas (quantitative data in [Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}). Parvalbumin (PV) immunostaining, which labels major populations of GABAergic neurons in several brain areas ([@bib14]), revealed a defect in Purkinje cell arborization and a deficit in basket and stellate GABAergic interneurons in *Thra*^*AMI/gn*^ cerebellum as expected from previous data ([@bib17], [@bib38]) ([Figure S4](#mmc1){ref-type="supplementary-material"}). A drastic reduction in the density of PV + neurons (90%--95% reduction relative to controls) was also visible in the hippocampus, cortex, and striatum of *Thra*^*AMI/gn*^ mice ([Figure 3](#fig3){ref-type="fig"}A). As a complement to PV labeling, we used *Wisteria floribunda* lectin (WFA) to label perineuronal nets, as it has been previously reported that a reduction in PV + neuron numbers may be accompanied by a persistence of these extracellular matrix structures ([@bib19]). In *Thra*^*AMI/gn*^ mice, WFA labeling was drastically reduced compared with that of control mice, but perineuronal nets were observed around PV-negative cell bodies ([Figure S5](#mmc1){ref-type="supplementary-material"}), suggesting that absence of PV labeling was not necessarily a sign of PV neuron loss. We also used antibodies directed against calretinin (CR), somatostatin (SST), and neuropeptide Y (NPY) to label other key populations of GABAergic neurons ([@bib33]). All GABAergic neuron subtypes investigated were affected but in a rather complex pattern. The density of CR + neurons was increased in the cortex and CA2-CA3 area of the hippocampus. In the hippocampal dentate gyrus, where CR + neurons are normally concentrated in the granular cell layer, the limits of this layer were ill-defined and CR + neurons spread into the molecular and polymorph layers ([Figure 3](#fig3){ref-type="fig"}B). The density of SST + neurons was also augmented in hippocampal dentate gyrus but not significantly altered in the cortex or striatum ([Figure 4](#fig4){ref-type="fig"}A). The density of NPY + neurons was significantly reduced in the cortex, but not in the striatum and hippocampus, where, by contrast, NPY immunoreactivity of the fibers increased ([Figures 4](#fig4){ref-type="fig"}B and [Table 1](#tbl1){ref-type="table"}).Table 1Relative Abundance of Several GABAergic Neuron Subtypes in *Thra*^*AMI/gn*^, Compared with Control, Mouse Brains at PND14, as Evidenced by ImmunohistochemistryCortexHippocampus (DG)Hippocampus (CA)StriatumControl*Thra*^*AMI/gn*^Control*Thra*^*AMI/gn*^Control*Thra*^*AMI/gn*^Control*Thra*^*AMI/gn*^Parvalbumin neuronal densityMean1.000.05[a](#tblfn1){ref-type="table-fn"}1.000.05[a](#tblfn1){ref-type="table-fn"}1.000.33[a](#tblfn1){ref-type="table-fn"}1.000.10[a](#tblfn1){ref-type="table-fn"}SD0.140.010.500.130.340.210.480.15*n*111011121110108Neuropeptide Y neuronal densityMean1.000.58[a](#tblfn1){ref-type="table-fn"}1.000.92NDND1.001.07SD0.000.110.000.06NDND0.110.20*n*5633NDND56Neuropeptide Y fluorescence intensityMeanNDND1.001.23[a](#tblfn1){ref-type="table-fn"}NDND1.001.31[a](#tblfn1){ref-type="table-fn"}SDNDND0.000.08NDND0.060.25*n*NDND33NDND66Calretinin neuronal densityMean1.000.75NDND1.004.90[a](#tblfn1){ref-type="table-fn"}NDNDSD0.120.54NDND0.414.10NDND*n*54NDND54NDNDSomatostatin neuronal densityMean1.001.121.002.55[a](#tblfn1){ref-type="table-fn"}1.001.081.001.16SD0.020.310.140.660.130.290.030.19*n*65656565[^2][^3]Figure 3Immunohistochemistry for Parvalbumin and CalretininImmunohistochemistry for parvalbumin (A) and calretinin (B) in PND14 *Thra*^*AMI/gn*^ and control mouse pups in selected brain regions. Right panels: scatterplots illustrating the relative density of immunoreactive cells in control (C, empty circles; blue lines for the mean and standard deviation) and mutant (M, filled triangles; red lines for the mean and standard deviation) mice. Calretinin-immunoreactive neurons could not be quantified in the dentate gyrus, due to the difficulty in delineating individual cells in this area. \*p \< 0.05. See also [Figures S4--S7](#mmc1){ref-type="supplementary-material"}.Figure 4Immunohistochemistry for Somatostatin and Neuropeptide YImmunohistochemistry for somatostatin (A) and neuropeptide Y (B) in PND14 *Thra*^*AMI/gn*^ and control mouse pups in the striatum, hippocampus, and cortex. Right panels: scatterplots illustrating the relative density of immunoreactive cells in control (C, empty circles; blue lines for the mean and standard deviation) and mutant (M, filled triangles; red lines for the mean and standard deviation) mice. \*p \< 0.05. See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.

Most of the above-mentioned immunohistochemistry experiments were also carried out in *Thra*^*Slox/gn*^ mice at PND14. In all instances, the defects observed in GABAergic neuron populations were the same as in *Thra*^*AMI/gn*^ mice (details in [Table S1](#mmc1){ref-type="supplementary-material"} and [Figure S6](#mmc1){ref-type="supplementary-material"}). In the surviving *Thra*^*Slox/gn*^ adult mice, PV and NPY immunohistochemistry indicated that the differentiation of neurons expressing these markers was not only delayed, but permanently impaired ([Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}). Taken together, these data indicate that expressing a mutant TRα1 alters the late steps of development of GABAergic neurons, reducing the numbers of PV+ and NPY + cells in some brain areas, while favoring an expansion of the SST+ and CR + cell populations. In the hippocampus, this is accompanied by subtle morphological alterations.

Changes in Gene Expression Caused by TRα1^L400R^ in GABAergic Neurons {#sec2.4}
---------------------------------------------------------------------

Because the impairment in GABAergic neuron differentiation does not appear to be restricted to a specific brain area or a specific neuronal GABAergic subpopulation, we hypothesized that a general mechanism might underlie the involvement of TH signaling in the terminal maturation of GABAergic neurons. In order to decipher this mechanism and identify the TRα1 target genes in GABAergic neurons, we first compared the transcriptome of the cortex in *Thra*^*AMI/gn*^ and control littermates at two different post-natal stages, PND7 and PND14, where we previously found clear histological alterations. Differential gene expression analysis pointed out a set of 58 genes whose expression was deregulated in *Thra*^*AMI/gn*^ mouse cortex, compared with age-matched control mice. Clustering analysis outlined contrasting patterns of regulations ([Figure S8](#mmc1){ref-type="supplementary-material"}). Exploring available single-cell RNAseq data (<https://singlecell.broadinstitute.org>) obtained from adult visual cortex ([@bib50]) suggests that a large part of the observed variations reflect the alterations in neuronal maturation already revealed by immunohistochemistry. For example, many downregulated genes are preferentially expressed in PV + neurons (*Akr1c18, Dusp10, Eya4*, *Flywch2, Me3, Ntn4, Pcp4L1, Ppargc1a, Pvalb, Stac2, Syt2*) whereas most overexpressed genes are preferentially expressed in SST+ and/or VIP + GABAergic interneurons (*Calb1, Cxcl14, Hap1, Klhl14, Pcdh8, Prox1, Rbp4, Rxfp3, Sema3c, Sst, Tac2, Zcchc12*). Interestingly, the analysis also revealed an upregulation of *Thra* at PND7 in control mice, which was absent in mutant mice. However, we expected a larger set of differentially expressed genes on the basis of previous *in vitro* analysis ([@bib23]). This probably results from the relatively low representation of GABAergic neurons among cortical cells. We thus decided to focus our investigation on the striatum, where the high abundance of GABAergic neurons, mainly spiny projection neurons, facilitates analysis. As expected, the same differential gene expression analysis identified a larger set of differentially expressed genes in the striatum (191 genes). A single factor Deseq2 analysis pointed out 126 genes whose expression was deregulated at PND7 in the striatum of *Thra*^*AMI/gn*^ mice, compared with age-matched control mice. At PND14, this number raised to 215 genes. Overall, 260 genes were found to be deregulated in the striatum of *Thra*^*AMI/gn*^ mice at either stage. Eight of these genes (*Cxcl14, Flywch2, Glra3, Ppargc1a, Prox1, Pvalb, Sst, Syt2*) were also deregulated in the cortex. Hierarchical clustering analysis of the striatum data mainly revealed a sharp transition between PND7 and PND14 in the striatum of control mice, which did not take place in *Thra*^*AMI/gn*^ mice ([Figure 5](#fig5){ref-type="fig"}).Figure 5Differentially Expressed Genes in the StriatumHierarchical clustering analysis of differentially expressed transcripts in the striatum of *Thra*^*AMI/gn*^ mice and control littermates at PND7 and PND14. The analysis is restricted to 260 genes for which the fold-change is \> 2 or \<0.5 (adjusted p value \< 0.05) for at least one developmental stage. High expression is in yellow, low expression is in blue, average in black. Note that the changes in gene expression between PND7 and PND14 are more conspicuous in control than in mutant mice, suggesting that a maturation process is blunted by the mutation. See also [Figure S8](#mmc1){ref-type="supplementary-material"} and [Tables S2](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

These differences in gene expression, as measured by Ampliseq, may have two origins. They can reflect deregulations of the expression of TRα1 target genes in GABAergic neurons, but they can also reflect various indirect consequences of these deregulations, such as a change in the composition of the cell population. In order to pinpoint the TRα1 target genes within the set of differentially expressed genes in striatum, we crossed the above results with a dataset obtained in wild-type mice, comparing different hormonal statuses. We assumed that the expression of TRα1 target genes should be quickly modified by changes in TH levels, whereas indirect consequences should be much slower. In the dataset, 181 genes were found to be deregulated in the striatum of hypothyroid mice, whereas 86 genes responded to a 2-day TH treatment of hypothyroid mice (Dataset S1). RT-qPCR was used to confirm some of these observations ([Tables S2--S4](#mmc1){ref-type="supplementary-material"}). In this dataset, however, the response of GABAergic neurons to TH cannot be distinguished from the response of other cell types present in the striatum, which also express TRα1. The overlap between the two datasets pointed out a set of 38 TH-activated genes whose expression pattern suggested a direct regulation by TRα1 in GABAergic neurons, whereas only 1 gene displayed an expression pattern that suggests a negative regulation by T3-bound TRα1 ([Figure 6](#fig6){ref-type="fig"}A).Figure 6Identifying a Core Set of TRα1 Target Genes in GABAergic Neurons of the Striatum by Combining RNAseq and Chip-Seq Analyses(A) RNAseq identifies a set of 38 genes, the expression pattern of which is fully consistent with a positive regulation by TRα1, and only 1 gene that has the opposite expression pattern.(B) Extract of the *Mus musculus* genome browser, around the *Hr* gene, a well-characterized TRα1 target gene. The 3 upper boxes indicate TRBSs identified as significant by the MACS2 algorithm. Note that a DR4-like element (lower track, red asterisks), as defined below, is found in only one of the 3 peaks.(C) Consensus sequence found in TRBSs identified by *de novo* motif search is close to the DR4 consensus (5′AGGTCANNNNAGGTCA-3′).(D) Combinations of RNAseq and Chip-Seq data. In the Venn diagrams, each fraction gives the number of genes with a proximal TRBS (\<30 kb for transcription start site, large lettering) and, among these genes, those in which a DR4 element was identified (small lettering). A set of 35 genes fulfill the criteria for being considered as genuine TRα1 target genes: they are downregulated in hypothyroid and mutant mice and upregulated after TH treatment of hypothyroid mice. For 17 of these genes, the TRBS contains a recognizable DR4-like element.See also [Data S1](#mmc2){ref-type="supplementary-material"} and [Tables S2--S5](#mmc1){ref-type="supplementary-material"}.

Identification of Direct TRα1 Target Genes in GABAergic Neurons of the Striatum {#sec2.5}
-------------------------------------------------------------------------------

To complete the identification of TRα1 target genes in striatal GABAergic neurons, we analyzed chromatin occupancy by TRα1 at a genome-wide scale by ChIPseq. Using *Thra*^*TAG/gn*^ mice, we precipitated the DNA/protein complexes, which contain the tagged TRα1 from the whole striatum, to address chromatin occupancy in GABAergic neurons only. This experiment revealed the existence of 7,484 chromatin sites occupied by TRα1^TAG^ (thyroid hormone receptor binding sites = TRBSs) in the genome ([Figure 6](#fig6){ref-type="fig"}B). In agreement with our previous study ([@bib13]) *de novo* motif discovery (<http://meme-suite.org/tools/meme-chip>) and enrichment analysis revealed a single consensus sequence for the binding of TRα1/RXR heterodimers. The sequence is the so-called DR4 element ([Figure 6](#fig6){ref-type="fig"}C). Assuming that proximity (\<30kb) between the TRα1^TAG^ binding site and the transcription start site is sufficient for direct transcriptional regulation by TRα1 would lead to consider a large fraction of genes as putative target genes (3,979/23,931 annotated genes in the mouse genome mm10 version; 16.6%). Among the 38 genes that are sensitive to TRα1^L400R^ expression and hypothyroidism and responsive to TH in hypothyroid mice, genes with a proximal TRBS were overrepresented (35/38: 92%; enrichment of 5.5 compared with the whole set of annotated genes). Interestingly, this enrichment was more striking if we considered only the TRBSs where a DR4 element was identified (3,813/7,484; 51%): DR4 elements were present within 30 kb of 7.5% of annotated genes (1,786/23,931) and of 45% of the putative TRα1 target genes identified in the present study (17/38) ([Figure 6](#fig6){ref-type="fig"}D). The same reasoning leads to the conclusion that the transcription of genes that are downregulated after T3 treatment is not regulated by chromatin-bound TRα1 ([Figure 6](#fig6){ref-type="fig"}D). Overall, the ChipSeq dataset suggests that a large fraction of the TRBS does not reflect the binding of TRα1/RXR heterodimers to DR4 elements but corresponds to other modes of chromatin association, which do not necessarily promote TH-mediated transactivation. However, as we cannot rule out that other types of response elements are also used, this analysis leaves us with 35 genes, which meet all the criteria for being considered as TRα1 direct target genes. Although some of these genes are known to have a neurodevelopmental function, they do not fall into a specific ontological category ([Table S5](#mmc1){ref-type="supplementary-material"}). This implies that TH promotes GABAergic neuron maturation by simultaneously acting on different cell compartments and cellular pathways.

Discussion {#sec3}
==========

Using two mouse models expressing mutant forms of TRα1 specifically in GABAergic neurons, we present evidence showing that TH, bound to TRα1, is required for the late steps of development of GABAergic neurons. As in the present study we have used GABAergic-specific somatic mutations, we can ascertain that the observed defects are cell-autonomous consequences of impaired TH signaling. We found that the defect in GABAergic differentiation is not restricted to a specific brain area, nor to a specific subtype of GABAergic neurons, as several subtypes of both projecting neurons and interneurons were affected by TRα1 mutations. This suggests that, although GABAergic neurons of different brain areas have different embryonal origins ([@bib34], [@bib37]), they share a common pathway of maturation that depends on TH/TRα1 signaling. Transcriptome analysis revealed a significant overlap between the regulated genes of mutant mice in the cortex, where most GABAergic neurons are interneurons, and in the striatum, which is mainly populated by projecting GABAergic neurons, i.e., medium spiny neurons.

These results extend previous findings, obtained either in hypothyroid rodents or in mice with *Thra* mutations, demonstrating the role of TH in GABAergic neurons in the cerebellum ([@bib17], [@bib36]), striatum ([@bib15]), cortex ([@bib56]), hippocampus ([@bib42]), and hypothalamus ([@bib28]). The major contribution of the present work is to demonstrate that the effect of TH/TRα1 on GABAergic neuron development is cell-autonomous. In many respects, neurodevelopmental damage caused by TRα1^L400R^ and TRα1^E395fs401X^ appears to be similar to, but more dramatic than, that reported for the ubiquitous TRα1^R384C^ mutation ([@bib56]), which is impaired in its affinity for TH, but possesses a residual capacity to transactivate gene expression ([@bib51]). The effects reported here with *Thra* knock-in mutations are also congruent with, although much stronger than, those previously reported in the brains of *Thra KO* mice ([@bib26]). This difference is not a surprise and has been previously shown to derive from the permanent transcriptional repression exerted by TRα1^L400R^ and TRα1^E395fs401X^ in presence or absence of TH ([@bib20]). The transcriptional repression effect exerted by unliganded TRα is completely lost in *Thra KO* mice, resulting in a much milder phenotype.

The present data indicate that TRα1 plays a major role in the late steps of development of several categories of GABAergic neurons. This is most obvious for PV + interneurons, which almost disappear from several brain areas in *Thra*^*AMI/gn*^ mice. However, their progenitors appear to be present, as evidenced by the use of tdTomato as a reporter for cells of the GABAergic lineage. Thus, we can exclude that TRα1 plays a major role in the first steps of GABAergic neuron development, i.e., progenitor proliferation and migration.

In the hippocampus, the density of tdTomato+ and CR + cells was higher in *Thra*^*AMI/gn*^ mice than in controls, and the limits of the granular layer were blurred. These results are congruent with previous studies. Indeed, blurring of the borders of the granular layers has been observed in hypothyroid rats ([@bib42]). An increase in CR + cells has also been reported in the hippocampus of mice expressing TRα^R384C^ ([@bib27]). Thus, we can speculate that TH signaling in GABAergic neurons plays a role in the process of lamination in the hippocampus. In particular, the increase in tdTomato + cells in the hippocampus of *Thra*^*AMI/gn*^ mice may result from impaired cell apoptosis, possibly affecting CR neurons.

The fate of the progenitors that fail to express PV in *Thra*^*AMI/gn*^ mice is unclear. One hypothesis is that they commit to a different GABAergic lineage. This could notably explain the excess of SST + cells in the hippocampus, because PV+ and SST + cortical interneurons share the same precursors ([@bib29], [@bib41]). However, the results obtained in the cortex do not support such hypothesis, because the density of SST + cells in the cortex did not differ between *Thra*^*AMI/gn*^ mice and their control littermates. An alternative hypothesis would be that the effects observed in different categories of GABAergic neurons are secondary to the near disappearance of PV + interneurons. Indeed, many defects caused by hypothyroidism in the brain are indirect, some of them being secondary to a defect in neurotrophin secretion in the microenvironment ([@bib5], [@bib24], [@bib43], [@bib57]).

Our genome-wide search pinpointed a small set of genes fulfilling the criteria, which lead us to consider them as genuine TRα1 target genes in GABAergic neurons: (1) the mRNA level of these genes is TH responsive, (2) it is decreased in the striatum of *Thra*^*AMI/gn*^ mice, and (3) TRα1 occupies a chromatin binding site located at a limited distance of their transcription start site. The last criterion is important, as it helps to differentiate between direct and indirect influences of TRα1 on gene regulation. Thus, we have addressed chromatin occupancy by TRα1 *in vivo*, in the striatum. Importantly, we have used a genetic strategy enabling to selectively identify GABAergic neuron-specific TRα1 binding to DNA within a heterogeneous tissue. The large number of chromatin binding sites that we have identified (7,484 TRBS) contrasts with the small set of 35 genes that we have identified as being directly regulated by TRα1 in GABAergic neurons. As we have used stringent statistical thresholds, we have probably overlooked some genuine TRα1 genes. For example, *Klf9* is a known target gene ([@bib12]), which is not present in our list, due to a below-threshold downregulation in the striatum of hypothyroid mice. However, even with liberal statistical thresholds, the number of presumptive target genes would not exceed 100, a number which is still small compared with the number of genes with a proximal TRBS. Such a contrast has previously been observed in other systems ([@bib1], [@bib13], [@bib25], [@bib47]) and suggests that only a small fraction of the TRBSs are involved in TH-mediated transactivation. Finally, the low level of correspondence between TRBSs and genes that are downregulated after T3 treatment ([Figure 6](#fig6){ref-type="fig"}D) suggests that the negative regulation of gene expression exerted by TH is not directly mediated by chromatin-bound TRα1, but perhaps an indirect consequence of the upregulation of transcription inhibitors. Further investigations will be required to better define these active TRBSs and better establish the correspondence between chromatin occupancy and transcriptional regulation by TRα1.

Most of the TRα1 target genes identified in the striatum have already been identified as being sensitive to the local TH level in various brain areas and at different developmental stages (see [Table S1](#mmc1){ref-type="supplementary-material"} in [@bib12]). This reinforces the hypothesis that they belong to a common genetic program that is regulated by TH, via TRα1, and that promotes the proper maturation of several categories of GABAergic neurons. Although their function in neurons is for a large part unknown, these genes can be grouped according to the putative function of their protein products: *Shh* and *Fgf16* encode secreted proteins, which play major roles in cellular interactions. *Sema7a* and *Nrtn* are involved in axon growth and pathfinding. Others are likely to define the electrophysiological properties of neurons by encoding ion channels *(Kctd17),* transporters of small metabolites *(Slc22a3, Slc26a10)*, or modulators of synaptic activity (*Nrgn, Lynx1).*

Overall, the broad influence of TRα1 mutations on GABAergic neuron differentiation and maturation is expected to greatly and permanently impair brain function, notably in the cortex, where a subtle equilibrium between different GABAergic neuron subtypes is necessary for normal development and plasticity ([@bib11]). In the mouse models presented here, epileptic seizures appear to be a main cause of mortality, which sheds light on the cause of the lethality that had been previously observed in mice with different *Thra* mutations ([@bib22], [@bib32], [@bib51]) as well as in mice suffering from complete TH deprivation ([@bib21], [@bib35]). Of note, the increase in NPY intensity that we have reported in the striatum and hippocampus of mutant mice may be secondary to the occurrence of epileptic seizures in these mice. Indeed, epileptic seizures are known to increase the expression of NPY in various brain regions, including the hippocampus ([@bib30], [@bib55]). The epileptic phenotype induced in mice by expressing a *Thra* mutation in GABAergic neurons is highly relevant to human pathology, as a history of epilepsy has been reported for several of the rare patients with a *THRA* mutation ([@bib40]). Autism spectrum disorders (ASD), whose comorbidity with epilepsy is well documented, have also been reported in these patients ([@bib31], [@bib58]). It is likely that these pathological traits are also due to a defect in GABAergic neuron maturation, and our data suggest that these patients might benefit from a treatment with GABA receptor agonists.

Limitations of the Study {#sec3.1}
------------------------

The modified *Thra* alleles used in the present study (*Thra*^*AMI*^, *Thra*^*Slox*^ and *Thra*^*TAG*^) result from an extensive remodeling of the *Thra* gene, which eliminates all the *Thra*-encoded proteins except for the mutated receptor. We have shown previously that such elimination of alternate splicing from the *Thra* locus resulted in a moderate overexpression of the mutant allele, compared with the wild-type allele. This overexpression is likely to lead to exaggerated phenotypic manifestations ([@bib38]). Such exaggerated phenotype has proved efficient in bringing to light key mechanisms by which TH/TRα1 signaling impacts brain development, but the clinical relevance of these mouse models is questionable. Importantly, a similar, albeit milder phenotype has been evidenced in GABAergic neurons of CRISPR/Cas9-generated mice with *Thra* mutations, which are more relevant models of the human RTHα disease ([@bib38]). Moreover, the epileptic phenotype observed in *Thra*^*AMI/gn*^ and *Thra*^*Slox/gn*^ mice appears to be congruent with the high occurrence of epilepsy, which has been reported in patients with RTHα ([@bib39], [@bib52]). Thus, the mouse models used in the present study appear as relevant for the study of the mechanisms of TH/TRα1 during brain development, even though they do not faithfully mimic the human disease.

A second limitation lies in the use of TRBSs as indicators of direct TRα1 target genes. The conventional strategy, which only takes into account the distance between a TRBS and the nearest transcription start site, has limited value, as nuclear receptors sometimes act at very long distances due to chromosomal looping ([@bib2], [@bib8], [@bib9]) Further investigations will be required to better define the correspondence between chromatin occupancy by TRα1 and transcriptional regulation.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

RNASeq and ChipSeq data are accessible through GEO Series accession number [GSE143933](ncbi-geo:GSE143933){#intref0020} (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143933>).
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